AIMS: The chemotherapy drug doxorubicin (Dox) is commonly used for treating a variety of human cancers; however, it is highly cardiotoxic and induces heart failure. We previously reported that the Bcl-2 mitochondrial death protein Bcl-2/19kDa interaction protein 3 (Bnip3), is critical for provoking mitochondrial perturbations and necrotic cell death in response to Dox; however, the underlying mechanisms had not been elucidated. Herein, we investigated mechanism that drives Bnip3 gene activation and downstream effectors of Bnip3-mediated mitochondrial perturbations and cell death in cardiac myocytes treated with Dox. METHODS AND RESULTS: Nuclear factor-κB (NF-κB) signalling, which transcriptionally silences Bnip3 activation under basal states in cardiac myocytes was dramatically reduced following Dox treatment. This was accompanied by Bnip3 gene activation, mitochondrial injury including calcium influx, permeability transition pore (mPTP) opening, loss of nuclear high mobility group protein 1, reactive oxygen species production, and cell death. Interestingly, impaired NF-κB signalling in cells treated with Dox was accompanied by protein complexes between Bnip3 and cyclophilin D (CypD). Notably, Bnip3-mediated mPTP opening was suppressed by inhibition of CypD-demonstrating that CypD functionally operates downstream of Bnip3. Moreover, restoring IKKβ-NF-κB activity in cardiac myocytes treated with Dox suppressed Bnip3 expression, mitochondrial perturbations, and necrotic cell death. CONCLUSIONS: The findings of the present study reveal a novel signalling pathway that functionally couples NF-κB and Dox cardiomyopathy to a mechanism that is mutually dependent upon and obligatorily linked to the transcriptional control of Bnip3. Our findings further demonstrate that mitochondrial injury and necrotic cell death induced by Bnip3 is contingent upon CypD. Hence, maintaining NF-κB signalling may prove beneficial in reducing mitochondrial dysfunction and heart failure in cancer patients undergoing Dox chemotherapy. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The chemotherapy drug doxorubicin (Dox) is commonly used for treating a variety of humancancers; however, it is highly cardiotoxic and induces heart failure. We previously reported that the Bcl-2 mitochondrial death protein Bcl-2/19kDa interaction protein 3 (Bnip3), is critical for provoking mitochondrial perturbations and necrotic cell death in response to Dox; however, the underlying mechanisms had not been elucidated. Herein, we investigated mechanism that drives Bnip3 gene activation and downstream effectors of Bnip3-mediated mitochondrial perturbations and cell death in cardiac myocytes treated with Dox. METHODS AND RESULTS: Nuclear factor-κB (NF-κB) signalling, which transcriptionally silences Bnip3 activation under basal states in cardiac myocytes was dramatically reduced following Dox treatment. This was accompanied by Bnip3 gene activation, mitochondrial injury including calcium influx, permeability transition pore (mPTP) opening, loss of nuclear high mobility group protein 1, reactive oxygen species production, and cell death. Interestingly, impaired NF-κB signalling in cells treated with Dox was accompanied by protein complexes between Bnip3 and cyclophilin D (CypD). Notably, Bnip3-mediated mPTP opening was suppressed by inhibition of CypD-demonstrating that CypD functionally operates downstream of Bnip3. Moreover, restoring IKKβ-NF-κB activity in cardiac myocytes treated with Dox suppressed Bnip3 expression, mitochondrial perturbations, and necrotic cell death. CONCLUSIONS: The findings of the present study reveal a novel signalling pathway that functionally couples NF-κB and Doxcardiomyopathy to a mechanism that is mutually dependent upon and obligatorily linked to the transcriptional control of Bnip3. Our findings further demonstrate that mitochondrial injury and necrotic cell death induced by Bnip3 is contingent upon CypD. Hence, maintaining NF-κB signalling may prove beneficial in reducing mitochondrial dysfunction and heart failure in cancerpatients undergoing Dox chemotherapy. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Hongying Gang; James Shaw; Rimpy Dhingra; James R Davie; Lorrie A Kirshenbaum Journal: Am J Physiol Heart Circ Physiol Date: 2013-04-12 Impact factor: 4.733
Authors: Rimpy Dhingra; Victoria Margulets; Subir Roy Chowdhury; James Thliveris; Davinder Jassal; Paul Fernyhough; Gerald W Dorn; Lorrie A Kirshenbaum Journal: Proc Natl Acad Sci U S A Date: 2014-12-08 Impact factor: 11.205
Authors: Tania Zaglia; Paola Ceriotti; Antonio Campo; Giulia Borile; Andrea Armani; Pierluigi Carullo; Valentina Prando; Raffaele Coppini; Vladimiro Vida; Tomas O Stølen; Wisløff Ulrik; Elisabetta Cerbai; Giovanni Stellin; Giuseppe Faggian; Diego De Stefani; Marco Sandri; Rosario Rizzuto; Fabio Di Lisa; Tullio Pozzan; Daniele Catalucci; Marco Mongillo Journal: Proc Natl Acad Sci U S A Date: 2017-10-09 Impact factor: 11.205
Authors: Georgios Amanakis; Junhui Sun; Maria M Fergusson; Shane McGinty; Chengyu Liu; Jeffery D Molkentin; Elizabeth Murphy Journal: Cardiovasc Res Date: 2021-01-01 Impact factor: 10.787
Authors: Inna Rabinovich-Nikitin; Mina Rasouli; Cristine J Reitz; Illana Posen; Victoria Margulets; Rimpy Dhingra; Tarak N Khatua; James A Thliveris; Tami A Martino; Lorrie A Kirshenbaum Journal: Autophagy Date: 2021-08-07 Impact factor: 13.391
Authors: Alyssa N Cavalier; Zachary S Clayton; David A Hutton; Devin Wahl; Daniel S Lark; Julie A Reisz; Simon Melov; Judith Campisi; Douglas R Seals; Thomas J LaRocca Journal: Exp Gerontol Date: 2021-06-18 Impact factor: 4.253